NOVKAN — Novakand Pharma AB Share News
0.000.00%
Last trade - 00:00- SEK5.40m
- -SEK10.67m
Brief: Kancera Signs Research And Option Agreement With Grünenthal
Brief: Kancera Q3 Operating Loss Narrows To SEK 10.6 Million
Brief: Kancera Signs LoI With USA-Based Private Investors
Brief: Kancera AB Has Been Awarded EU Funding
Brief: Kancera AB Q2 Operating Loss Narrows To SEK 10.2 Million
Brief: Kancera: Blockers Of Fractal System Have Been Patented
Brief: Kancera Q1 Operating Loss Widens To SEK 12.5 Million
Brief: Kancera Raises SEK 48 Million In New Issue
Brief: Kancera AB Patent Application For Extended Product Protection And New Product Formulation For Kand567
Brief: Kancera Proposes Rights Issue Of SEK 60 Million
Brief: Kancera Q4 Operating Loss Widens To SEK 11.9 Million
Brief: Kancera Acquires Full Rights To Fractalkine Project
Brief: Kancera: 2 mln shares issued to Acturum Real Estate
Brief: Kancera Q3 operating loss widens to SEK 16.6 million
Brief: Recipharm, Kancera cooperate to manufacture clinical trial supply
Brief: Kancera Q2 pre-tax loss widens to SEK 18.0 mln
Brief: Kancera to carry out a smaller new issue of up to SEK 24 million
Brief: Kancera Q4 operating loss widens to SEK 6.5 million
Brief: Kancera: positive results with fractalkine blocker KAN0440567 in preclinical models of pain caused by anti-cancer drugs